According to the National Health and Nutrition Examination Survey (NHANES) , fewer than 2 percent of U.S
Department of Medicine, University Medical Centre Mainz, Johannes Gutenberg University, Mainz, Germany, Mainz, Germany Background: Fib-4 was developed as a non-invasive biomarker to predict advanced fibrosis in other liver disease and was consequently adopted in nonalcoholic fatty liver disease (NAFLD) / nonalcoholic steatohepatitis (NASH) by international guidelines
Not suitable during or during a planned pregnancy, as well as breastfeeding.
9.Tian G, Sawashita J, Kubo H, Nishio SY, Hashimoto S, Suzuki N, Yoshimura H, Tsuruoka M, Wang Y, Liu Y, Luo H, Xu Z, Mori M, Kitano M, Hosoe K, Takeda T, Usami S, Higuchi K